English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA global phase 3 clinical trial that included Ann & Robert H. Lurie Children’s Hospital of Chicago found that a year-long immunotherapy through a skin patch safely desensitized toddlers with peanut allergy, lowering the risk of a severe allergic reaction from accidental exposure. Results of this randomized, double-blind, placebo-controlled trial for children 1-3 years of age, funded by DBV Technologies, were published in the New England Journal of Medicine.
Tag: Peanut Allergy
Four Years After Release of Guidelines, Parents Still Not Informed About Early Peanut Introduction
A new study being presented at this year’s ACAAI Annual Scientific Meeting reveals that although 58% of those surveyed reported their primary care physician discussed early peanut introduction, only 40% of the parents said they received a recommendation to introduce peanut by 11 months of age.
New Estimates of ‘Safe’ Levels of Exposure to Peanut Protein for U.S. Population
Paper on dose-response relationship evaluated for peanut allergy in clinical trial screening published
Research News Tip Sheet: Story Ideas from Johns Hopkins Medicine
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every other Wednesday.
Making wheat and peanuts less allergenic
Research uses plant breeding and biotechnology to remove proteins associated with food allergies.
Approximately A Third of Pediatricians Fully Follow Guidelines on Peanut Allergy Prevention in Infants
While 93 percent of U.S. pediatricians surveyed were aware of the national guidelines on peanut allergy prevention in infants, only 30 percent were fully implementing the recommended practices and 64 percent reported partial implementation, according to the study published in JAMA Network Open.
FDA approves peanut allergy treatment for children and teens
The University of Chicago Medicine Comer Children’s Hospital was one of the sites for a landmark clinical trial that led to approval of the first oral immunotherapy treatment for peanut allergy in children and teens.
New FDA-Approved Oral Immunotherapy Marks Important Milestone in Peanut Allergy Management
The U.S. Food and Drug Administration (FDA) approved Palforzia, a peanut powder product designed to help reduce peanut-induced allergic reactions.
Although Palforzia just received FDA approval, Nuvance Health allergists/immunologists have been offering oral immunotherapy (OIT) for various food allergies for five years.
By slowly increasing a person’s tolerance to an allergen over time, OIT can lower the risk of having a severe allergic reaction. This lowered risk may help reduce anxiety for kids with food allergies, as well as their family members and caregivers.
CHOP Doctors Available to Speak About New FDA Approved Treatment for Peanut Allergies
Philadelphia, February 3, 2020 – The U.S. Food & Drug Administration (FDA) announced the approval PalforziaTM, a first-of-its-kind treatment for peanut allergies. Over the course of the past decade, researchers with the Allergy Program at Children’s Hospital of Philadelphia (CHOP)…
Forty Percent of People with Peanut Allergies Can Eat Tree Nuts but Choose to Avoid Them
Nearly 90 percent of peanut-allergic individuals in the study could potentially tolerate almonds, but 33 percent preferred strict avoidance due to fear of an allergic reaction.